Additional file 1 of Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome

Additional file 1. Table S1. Detailed summary of clinical parameters and patient data in ccRCC cohort. Table S2. Summary of ccRCC patients, number of FFPE blocks, and number of studied regions per block. Table S3. Detailed summary of mutations for each ccRCC patient. Table S4. List of 8,749 differentially methylated CpGs between ccRCC tumors and normals. Data are provided as a subset of Illumina EPIC array. Table S5. Detailed summary of medical history and patient data in normal kidney cohort. Table S6. List of 5,000 most variable CpGs in the intermediate ICC group. Data are provided as a subset of Illumina EPIC array. Table S7. List of 819 CpGs in the intermediate ICC groupassociated with survival in the TCGA-KIRC dataset. Data are provided as a subset of Illumina 450K array. Table S8. List of 435 GeneHancer CpGs conserved in at least any combination of 4 tumors. Data are provided as a subset of Illumina EPIC array. Table S9. List of 236 GeneHancer CpGs interacting with the gene they are located in. Data are provided as a subset of Illumina EPIC array. Table S10. List of 49 GeneHancer CpGs interacting with the gene they are located in and associated with better survival. Data are provided as a subset of Illumina 450K array. Table S11. Summary of Gerlinger and Gulati CNVs in ccRCC regions for each patient.